Business
Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin’s
About this update from Adaptive Biotechnologies Corporation
[{"type":"text","content":"Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin’s Lymphoma\nSEATTLE, June 03, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in more than 20 abstracts studying the use of Adaptive’s clonoSEQ® Assay for minimal residual disease (MRD) assessment at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, and the European Hematology Association (EHA) Virtual Congress from June 9-17. clonoSEQ is the first and only U.S. Food and Drug Administration (FDA)-cleared assay for MRD assessment in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (B-ALL), and is widely available to clinicians and patients across the U.S. “What is particularly notable at ASCO and EHA this year is the breadth of clinical use cases for MRD that are represented,” said Lance Baldo, MD, Chief Medical Officer of Adaptive Biotechnologies. “Both clinician investigators and pharmaceutical companies have found new settings in which deep responses by clonoSEQ are achievable, which is excellent news for patients and also evidence of the growing role that clonoSEQ MRD monitoring can play across the lymphoid cancer care continuum.” Assessment of MRD is a way to directly detect and quantify remaining disease, even in the absence of symptoms, across a spectrum of blood cancers. A patient’s MRD status gives clinicians information about how a patient may be responding to treatment, so patients and providers can be in control when it comes to managing the disease and treatment decisions. Data at ASCO and EHA illustrates the relevance of MRD assessment post-CAR T cell therapy, in MM patients who are often heavily pretreated and who in the past might not have been expected to have such deep responses. Similarly, data showing the ability to achieve deep responses in high-risk patients supports the growing range of patient settings in which MRD assessment is valuable. Both meetings also include data showcasing the importance of serial monitoring of MRD using clonoSEQ as a primary endpoint. These data demo...